EDITORIAL

238 Maintaining the metabolic homeostasis of *Helicobacter pylori* through chronic hyperglycemia in diabetes mellitus: A hypothesis

*Reshetnyak VI, Maev IV*

SYSTEMATIC REVIEWS

244 Disordered eating behaviour and eating disorder among adolescents with type 1 diabetes: An integrative review

*Oliveira Cunha MCS, Dutra FCS, Cavaleiro Brito LMM, Costa RF, Gaspar MWG, Sousa DF, Moura de Araújo MF, Queiroz MVO*
ABOUT COVER
Editorial Board Member of World Journal of Meta-Analysis, Yun-Xian Yu, MD, PhD, Associate Professor, Department of Epidemiology and Health Statistics, Medicine School, Zhejiang University, Hangzhou 310016, Zhejiang Province, China. 13735875136@163.com

AIMS AND SCOPE
The primary aim of World Journal of Meta-Analysis (WJMA, World J Meta-Anal) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality meta-analysis and systematic review articles and communicate their research findings online.

WJMA mainly publishes articles reporting research results and findings obtained through meta-analysis and systematic review in a wide range of areas, including medicine, pharmacy, preventive medicine, stomatology, nursing, medical imaging, and laboratory medicine.

INDEXING/ABSTRACTING
The WJMA is now abstracted and indexed in Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Hua-Ge Yu; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

<table>
<thead>
<tr>
<th>NAME OF JOURNAL</th>
<th>INSTRUCTIONS TO AUTHORS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ISSN</th>
<th>GUIDELINES FOR ETHICS DOCUMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISSN 2308-3840 (online)</td>
<td><a href="https://www.wjgnet.com/bpg/gerinfo/287">https://www.wjgnet.com/bpg/gerinfo/287</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LAUNCH DATE</th>
<th>GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>FREQUENCY</th>
<th>PUBLICATION ETHICS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bimonthly</td>
<td><a href="https://www.wjgnet.com/bpg/gerinfo/288">https://www.wjgnet.com/bpg/gerinfo/288</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EDITORS-IN-CHIEF</th>
<th>PUBLICATION MISCONDUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saurabh Chandan, Jing Sun</td>
<td><a href="https://www.wjgnet.com/bpg/gerinfo/208">https://www.wjgnet.com/bpg/gerinfo/208</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EDITORIAL BOARD MEMBERS</th>
<th>ARTICLE PROCESSING CHARGE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PUBLICATION DATE</th>
<th>STEPS FOR SUBMITTING MANUSCRIPTS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>COPYRIGHT</th>
<th>ONLINE SUBMISSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>© 2022 Baishideng Publishing Group Inc</td>
<td><a href="https://www.f6publishing.com">https://www.f6publishing.com</a></td>
</tr>
</tbody>
</table>
Maintaining the metabolic homeostasis of *Helicobacter pylori* through chronic hyperglycemia in diabetes mellitus: A hypothesis

Vasiliiy Ivanovich Reshetnyak, Igor Veniaminovich Maev

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report’s scientific quality classification**
- Grade A (Excellent): 0
- Grade B (Very good): 0
- Grade C (Good): C
- Grade D (Fair): D, D
- Grade E (Poor): 0

**P-Reviewer:** Lauro D, Italy; Rwegerera GM, Botswana

**Received:** August 4, 2022

**Peer-review started:** August 4, 2022

**First decision:** August 19, 2022

**Revised:** August 23, 2022

**Accepted:** September 21, 2022

**Article in press:** September 21, 2022

**Published online:** October 28, 2022

**Abstract**

*Helicobacter pylori* (*H. pylori*) infection occurs in almost half of the world’s population, most of whom are merely carriers of this microorganism. *H. pylori* is shown to be detected more frequently in patients with diabetes mellitus (DM) than in the general population, which is accompanied by a significantly increased risk of developing *H. pylori*-associated diseases. In addition, eradication therapy shows a low efficiency for *H. pylori* infection in patients with DM. There is a relationship between the level of chronic hyperglycemia and a higher detection rate of *H. pylori* as well as a lower efficiency of eradication therapy in patients with DM. The exact mechanisms of these phenomena are unknown. The authors make a hypothesis that explains the relationship between chronic hyperglycemia and the increased detection rate of *H. pylori*, as well as the mechanisms contributing to the improved survival of this bacterium in patients with DM during eradication therapy.

**Key Words:** *Helicobacter pylori*; Diabetes mellitus; Glycated hemoglobin A; *H. pylori* eradication; Amino acids and glucose as nutrients for *H. pylori*

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** The authors hypothesize that in patients with diabetes mellitus (DM), *Helicobacter pylori* (*H. pylori*) are most likely to rely on both amino acids and glucose for its vital activity. The hypothesis makes it possible to explain the high detection rate of *H. pylori* in patients with DM, as well as the lower efficiency of eradication therapy in them.
INTRODUCTION

Forty years have passed since the description of Helicobacter pylori (H. pylori) as a pathogen in the development of atrophic gastritis and peptic ulcer disease[1-3]. It has been shown that H. pylori infection occurs in almost half of the population in the world, most of whom are merely carriers of this microorganism[4,5]. In addition, many researchers have indicated that H. pylori are detected more frequently in patients with diabetes mellitus (DM) than in the general population[6-12]. At the same time, there are studies which report reverse results about the incidence of type 2 DM (T2DM) in H. pylori-positive patients[13-15]. However, the relationship between H. pylori infection and the risk of developing T2DM remains controversial and ambiguous. Hence, a prospective cohort study by Jeon et al[16] has shown that H. pylori infection correlates with a high risk of T2DM. Similarly, a meta-analysis carried out by Mansori et al[17] suggests that H. pylori may be one of the risk factors for T2DM. On the contrary, other studies report that H. pylori is not associated with either insulin resistance or the prevalence of T2DM[18-20]. Data from Tamura et al[21] suggest that East Asian CagA-positive H. pylori infection is not a risk factor for T2DM. The successful H. pylori eradication rates in patients with type 1 and type 2 DM are 62% and 50%, respectively, which are much lower than those in people without these two forms of the disease[22-25]. The low efficiency of eradication therapy for H. pylori infection in diabetic patients is uniquely presented in many studies[26-29].

There is a clear correlation between the higher detection rate of H. pylori in diabetic patients and lower efficacy of eradication therapy, depending on the level of hyperglycemia[10,13,29]. Uncontrolled diabetes with the development of chronic hyperglycemia causes a number of metabolic changes[30]. Chronic hyperglycemia in turn leads to increased susceptibility to infective agents in diabetic patients[9,10,30,31]. The exact mechanisms underlying the link of chronic hyperglycemia and the higher detection rate of H. pylori, as well as the mechanisms that improve the survival of this bacterium in diabetic patients during eradication therapy remain unknown. An understanding of how chronic hyperglycemia is related to the maintenance of the metabolic homeostasis of H. pylori for its vital activity and reproduction in diabetic patients is of great scientific and practical importance.

It is hypothesized that chronic hyperglycemia is associated with: (1) The increased detection rate of H. pylori; (2) possible metabolic changes in the bacterial cells; and (3) the results of eradication therapy.

It is well known that H. pylori colonizes the gastric mucosa. To establish long-term colonization, the bacterium must sense and adapt to the nutritional conditions that exist in its habitat. Surprisingly, little attention has been paid to the preferred sources of nutrients and energy for the life, growth, and reproduction of H. pylori, as well as changes in the source of food ingredients and energy for H. pylori in diabetic patients. The available data suggest that for its life, growth, and reproduction, H. pylori utilizes amino acids and carboxylic acids, which are produced in sufficient quantities in the stomach as a result of hydrolysis of food proteins[32-34]. H. pylori catabolize a large amount of amino acids with the most substantial being alanine, arginine, asparagine, aspartate, glutamate, glutamine, proline, and serine[32,35-37]. H. pylori can also catabolize fumaric acid[38], malic acid[35], and lactic acid[39]. Thus, amino acids and carboxylic acids are sources of carbon, nitrogen, and energy.

In a healthy individual, H. pylori are almost independent of sugars, such as glucose[32-34]. However, glucose is known to be one of the most important carbohydrates, which is used for life by many microorganisms, including inhabitants in the digestive system. Moreover, Wang et al[40] believe that glucose plays a key role in the outcome of bacterial infection in humans. A question is raised as to whether H. pylori can utilize glucose as a plastic and energy material. Studies conducted in the 1990s and later indicate that H. pylori has enzyme systems capable of utilizing carbohydrates, D-glucose in particular[41-43]. These data suggest that in its evolutionary phylogenetic development and adaptation to life and reproduction in the stomach, H. pylori not only acquire the ability to restructure its metabolism for the use of amino acids as a plastic and energy material, but most probably retain the ability to utilize carbohydrates for their life activity. There are experimental data showing that adding glucose to the nutrient medium when growing H. pylori, enhances its growth[29,44].

Chronic hyperglycemia in diabetic patients involves compensatory mechanisms aimed at normalizing the blood level of glucose[5]. To remove excess glucose in patients with DM and chronic hyperglycemia, it is most likely that the extradigestive (excretory) function of the gastric mucosa is switched on. This leads to the fact that in patients with DM and chronic hyperglycemia, H. pylori gain advantages for its growth, reproduction, and survival as it can use not only amino acids for its life, but also glucose available in excess in patients with DM. This hypothesis may explain the more frequent detection of H. pylori in patients with DM than in the general population.

Citation: Reshetnyak VI, Maev IV. Maintaining the metabolic homeostasis of Helicobacter pylori through chronic hyperglycemia in diabetes mellitus: A hypothesis. World J Meta-Anal 2022; 10(5): 238-243
URL: https://www.wjgnet.com/2308-3840/full/v10/i5/238.htm
DOI: https://dx.doi.org/10.13105/wjma.v10.i5.238
Based on this hypothesis, it is possible to explain also the lower efficiency of eradication therapy in patients with DM.

\textit{H. pylori} eradication regimens contain antibacterial drugs (clarithromycin, metronidazole, bismuths, etc.) and agents that reduce hydrochloric acid production. The use of antacids aimed at creating optimal conditions for acid-dependent antibacterial agents\cite{45-48}. The data presented in recent studies suggest that it is extremely important to determine gastric pH for \textit{H. pylori} eradication\cite{45,46}. In addition, the antacids have a double effect on \textit{H. pylori} with an opposite effect. Increased gastric pH is a favorable factor for the vital activity of \textit{H. pylori}. But at the same time, the antacids deprive \textit{H. pylori} of nutrients. Exposure to hydrochloric acid in the stomach causes denaturation of food proteins and initiates their hydrolysis by the gastric juice enzymes pepsin and gastrixin. This gives rise to oligopeptides with different lengths and to a certain amount of amino acids, which are utilized by \textit{H. pylori} for its life activity. Taking antacids practically does not lead to denaturation of food proteins. Consequently, the rate of protein hydrolysis is considerably reduced. As a result, the stomach practically does not produce amino acids that are essential for maintaining the vital activity of \textit{H. pylori}. The lack of nutrients and the intake of antibacterial drugs result in the death of the microorganism or in its transition to a dormant form\cite{49}. The latter is rare during powerful antibiotic therapy.

There is an opportunity for \textit{H. pylori} to utilize glucose as an energy and plastic material in diabetic patients receiving eradication therapy against the underlying chronic hyperglycemia and amino acid deficiency. It is likely that this mechanism enables this microorganism to successfully survive the extreme conditions of eradication. But this can happen only in the presence of chronic hyperglycemia. That is to say, the survival of \textit{H. pylori} under extreme conditions of eradication should depend on the level of hyperglycemia. And the longer period of hyperglycemia is, the more likely \textit{H. pylori} survive the extreme conditions of eradication.

Chronic hyperglycemia can be assessed by the blood level of glycated hemoglobin A (HbA1c) (Figure 1). The HbA1c level is the result of nonenzymatic glycosylation of hemoglobin, with the formation of a bond between glucose and the free N-terminal proline amino group in the hemoglobin $\beta$-chain\cite{50}. The indicator plays an important role in monitoring the time course of changes in blood glucose levels in diabetic patients and for evaluation of the efficacy of hypoglycemic drugs\cite{51}. In 2011, the World Health Organization officially recommended an HbA1c level of $\geq 6.5\%$ as a diagnostic cut-off value for DM\cite{52}. This indicator reflects the integrated blood glucose level for the last 3-4 mo\cite{53-55}.

The association between \textit{H. pylori} infection and HbA1c in diabetic patients has been confirmed in many studies\cite{51,56,57}. Glycated hemoglobin A levels were significantly higher in patients with DM and \textit{H. pylori} infection than in those with DM and without \textit{H. pylori} infection (WMD = 0.50, 95\%CI: 0.28-0.72, $P < 0.001$)\cite{51}. Subgroup analysis by the subtype of DM has revealed a correlation between \textit{H. pylori} infection and an elevated glycated hemoglobin A level in type 1 DM ($F = 74\%$, $P < 0.001$, WMD = 0.46, 95\%CI: 0.12-0.80) and in T2DM ($F = 90\%$, $P < 0.001$, WMD = 0.59, 95\%CI: 0.28-0.90, $P < 0.001$)\cite{51}.

Bektemirova et al\cite{58} used the HbA1c level to evaluate the efficacy of hypoglycemic drugs taken by 83 patients with T2DM and \textit{H. pylori}-associated diseases during eradication therapy. Glycated hemoglobin A was shown to reach a target level of $< 6.5\%$ in 62 of the 83 examinees, while it remained elevated ($> 7.0\%$) in 21 patients. This means that despite the use of hypoglycemic drugs, the level of hyperglycemia persisted in these patients for at least 2-3 mo. And it was in these patients who did not reach the target HbA1c level had a significantly ($P < 0.017$) lower efficiency of eradication therapy than those who achieved the target level of HbA1c $< 6.5\%$. The data obtained by Bektemirova et al\cite{58} indirectly suggest that \textit{H. pylori} most likely take advantage of chronic hyperglycemia to survive under the extreme conditions of eradication.

According to Tseng, the use of insulin to normalize blood glucose levels in patients with T2DM substantially increases the rate of \textit{H. pylori} eradication compared to those with DM without insulin administration\cite{25}. The higher efficiency of \textit{H. pylori} eradication in T2DM patients taking insulin suggests that these patients are more likely to normalize their blood glucose levels during insulin therapy. And this is most likely to cause an increase in the efficiency of \textit{H. pylori} eradication.

\textbf{CONCLUSION}

The data available in the literature advance the following hypothesis that in diabetic patients, \textit{H. pylori} are most likely to utilize both amino acids and glucose for its vital activity. The hypothesis makes it possible to explain the high detection rate of \textit{H. pylori} in diabetic patients, as well as their lower eradication therapy efficiency. Undoubtedly, this hypothesis requires further conformations by biochemical, microbiological, molecular genetics, and other studies. Further multicenter studies are needed to confirm this hypothesis. But if this hypothesis is correct, then before \textit{H. pylori} are eradicated in DM patients, there is a need for mandatory monitoring and targeted correction of blood glucose and HbA1c levels according to the algorithm given in Figure 1. The algorithm can be used for the management of patients with DM and concomitant \textit{H. pylori}-associated diseases, which is of great practical importance for their successful eradication therapy.
Figure 1 Algorithm for monitoring and targeted correction of glycated hemoglobin A levels in patients with diabetes mellitus and *Helicobacter pylori*-associated diseases. *H. pylori*: *Helicobacter pylori*.

ACKNOWLEDGEMENTS

The authors express their gratitude to Alexandr Igorevich Burmistrov for technical assistance in preparing this article.

FOOTNOTES

**Author contributions:** All the authors have equally contributed to the study conception and design, literature review and analysis, manuscript drafting, critical revision and editing, and approval of the final version.

**Conflict-of-interest statement:** All authors declare that they have no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** Russia

**ORCID number:** Vasiliy Ivanovich Reshetnyak 0000-0003-3614-5052; Igor Veniaminovich Maev 0000-0001-6114-564X.

**S-Editor:** Liu JH
**L-Editor:** Ma JY-MedE
**P-Editor:** Liu JH

REFERENCES


Reshetnyak VI et al. Metabolic homeostasis of *H. pylori* in diabetes mellitus


Keilberg D, Steele N, Fan S, Yang Ch, Zavros Y, Ottemann KM. Gastric metabolomics analysis supports H. pylori’s catabolism of organic and amino acids in both the corpus and antrum. *bioRxiv* 2020; 183553 [DOI: 10.1101/2020.07.01.183553]


Chávez-Reyes J, Escárciga-González CE, Chavira-Suárez E, León-Buitimea A, Vázquez-León P, Morones-Ramírez JR,


37 Nagata K, Nagata Y, Sato T, Fujino MA, Nakajima K, Tamura T. L-Serine, D- and L-proline and alanine as respiratory substrates of Helicobacter pylori: correlation between in vitro and in vivo amino acid levels. *Microbiology (Reading)* 2003; 149: 2023-2030 [PMID: 12904542 DOI: 10.1099/mic.0.26203-0]


